Laxmi S. Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laxmi S. Mehta has a total of 281 co-authors. Here are the top co-authors by number of shared publications:
- Garima Sharma
Inova Schar Heart and Vascular, Inova Health System, Falls Church, Virginia, USA
8 shared publications Athena Poppas
Division of Cardiology, Brown University, Providence, Rhode Island, USA
5 shared publicationsJennifer H. Mieres
Department of Cardiology at Northwell, Zucker School of Medicine, Lake Success, New York, USA
5 shared publications- Allison Bigeh
Division of Cardiovascular Medicine, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA
4 shared publications Kimberly A. Skelding
4 shared publications- Mamas Andreas Mamas
Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom
4 shared publications
Latest Publications
- 26 October 2026
- Published by Wolters Kluwer Health in Circulation
Promises to Keep: Closing the Gaps in Women’s Cardiovascular Health
- 26 October 2026
- Published by Wolters Kluwer Health in Circulation
Promises to Keep: Closing the Gaps in Women’s Cardiovascular Health
- Open Access
- 17 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103343
Workforce Culture and Engagement
- 17 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103343
Open AccessWorkforce Culture and Engagement
- Open Access
- 12 September 2026
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 101 (11) , 2077-2081
Chief Wellness Officer Roles and Organizational Structures: Insights From the CHARM Network Survey
- 12 September 2026
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 101 (11) , 2077-2081
Open AccessChief Wellness Officer Roles and Organizational Structures: Insights From the CHARM Network Survey
- Open Access
- 19 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102340
Spectrum of Perceptions Regarding Professional Climate
- 19 November 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102340
Open AccessSpectrum of Perceptions Regarding Professional Climate
- Open Access
- 8 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101724
Future of Stroke Prevention
- 8 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101724
Open AccessFuture of Stroke Prevention
- Open Access
- 18 March 2025
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 19 (1)
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Purpose of Review: Obesity pharmacotherapy is rapidly evolving with the ability of glucagon-like peptide- 1 receptor agonists (GLP-1RAs) to improve atherosclerotic cardiovascular disease (ASCVD) outcomes. This review focuses on how GLP-1RAs impact lipid-related outcomes. Recent Findings: Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia. The SELECT trial has shown reduction in major adverse cardiovascular events. This and other trials have shown improvements in patients’ lipid profiles with the most pronounced impact on reduction of triglycerides. Summary: Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world. GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction. The positive impact of GLP-1RA therapy on lipids is an important contributor to these outcomes.
- 18 March 2025
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 19 (1)
Open AccessThe Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Purpose of Review: Obesity pharmacotherapy is rapidly evolving with the ability of glucagon-like peptide- 1 receptor agonists (GLP-1RAs) to improve atherosclerotic cardiovascular disease (ASCVD) outcomes. This review focuses on how GLP-1RAs impact lipid-related outcomes. Recent Findings: Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia. The SELECT trial has shown reduction in major adverse cardiovascular events. This and other trials have shown improvements in patients’ lipid profiles with the most pronounced impact on reduction of triglycerides. Summary: Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world. GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction. The positive impact of GLP-1RA therapy on lipids is an important contributor to these outcomes.
- Open Access
- 17 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (4) , 101666
Workplace Mistreatment in U.S. Cardiology
- 17 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (4) , 101666
Open AccessWorkplace Mistreatment in U.S. Cardiology
- Open Access
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (18) , e036874
Dual Indicators of Well‐Being: Leading With Fulfillment, Lagging With Burnout
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (18) , e036874
Open AccessDual Indicators of Well‐Being: Leading With Fulfillment, Lagging With Burnout
- Open Access
- 23 February 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (7) , 102268
Diagnostic and Management Considerations in a High-Risk Pregnant Patient With Ischemic Cardiomyopathy
- 23 February 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (7) , 102268
Open AccessDiagnostic and Management Considerations in a High-Risk Pregnant Patient With Ischemic Cardiomyopathy
- 20 February 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (6) , 1031-1042
Addressing Social Determinants of Health in Maternal Cardiovascular Health
- 20 February 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (6) , 1031-1042
Addressing Social Determinants of Health in Maternal Cardiovascular Health